What is IBIO's market cap?

$51.45M, based on the Nov 4 close of $0.80.

Does iBio pay a dividend?

No regular cash dividend has been paid in the last year.

How much of IBIO is sold short?

3.7M shares, 6.8% of float, as of Oct 15, 2026.

What sector is IBIO in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · IBIOHealthcarePharmaceuticals

iBio, Inc. Common Stock (IBIO)

$0.8000−2.85%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$0.80▼ 47.71% in range

Nov 4, 2025Low $0.71 · High $3.07Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

iBio closed at $0.80 on Nov 4, down 2.85%, 73.9% below its 52-week closing high. Volume of 278.0K shares was 0.35× its 20-day average (below normal).

Split-adjusted performance: -23.8% over one month, -54.8% over six months, -54.5% over one year.

Short interest was 3.7M shares at the Oct 15 settlement, down 11.2% from the prior report (6.8% of float, 3.5 days to cover).

Market cap$51.4M64.3M shares

Revenue · quarter$0.00−100.0% YoY

Diluted EPS$-0.04—

P/E · TTM—P/S 514.5×

Net margin—

Dividend yieldNone

52-week range0.71 – 3.07−73.9% from high

Volume278.0K0.35× 20-day avg

Volatility · 60d65.6%Annualised

Short % of float6.8%3.5 days to cover

Net cash$88.0MCash $88.0M

Next earnings—Not scheduled

Split-adjusted performance

1W −0.5%1M −23.8%3M −42.4%6M −54.8%YTD −58.5%1Y −54.5%3Y −84.3%5Y −99.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum21

Revenue growth7

Net margin—

Value (low P/E)—

Size30

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short3.7M−11.2% vs prior

Days to cover3.5Settled Oct 15

% of float6.8%

Short vol. 10d60.8%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
IBIOiBio	$0.8000	−2.85%	−54.8%	−100.0%	—	—	$51.4M
ANVSAnnovis Bio	$1.21	+11.01%	−49.6%	—	—	—	$51.6M	Compare
PLRXPliant Therapeutics	$0.8518	−1.03%	−30.7%	—	—	—	$52.7M	Compare
HOWLWerewolf Therapeutics	$1.09	+1.87%	+67.6%	—	17.5%	—	$53.0M	Compare
OSTXOS Therapies Incorporated	$1.15	−0.86%	−33.5%	—	—	—	$53.8M	Compare
CNTBConnect Biopharma Holdings Limited	$0.7805	+0.83%	−68.5%	+5666.7%	−624.4%	—	$49.2M	Compare
TLPHTalphera	$1.05	+0.96%	+20.7%	—	—	—	$54.5M	Compare
GANXGain Therapeutics	$1.11	−3.48%	−41.9%	—	—	—	$48.4M	Compare
INMInMed Pharmaceuticals	$8.75	+420.83%	+1104.6%	—	—	—	$48.1M	Compare

News about iBio

All news →

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate UpdateGlobeNewswire Inc. · Aug 28, 2026▲ Positive

Quick answers

What does iBio do?: iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease.
What is IBIO's market cap?: $51.45M, based on the Nov 4 close of $0.80.
Does iBio pay a dividend?: No regular cash dividend has been paid in the last year.
How much of IBIO is sold short?: 3.7M shares, 6.8% of float, as of Oct 15, 2026.
What sector is IBIO in?: Healthcare, in the Pharmaceuticals industry.

About iBio

iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.

HQ: New York, NY23 employeesListed Aug 19, 2008ibioinc.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology